CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
If your budget isn't functioning, it's time for a change. Explore effective strategies to fix your budget and regain control of your finances.
13,885 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
MicroStrategy's crypto treasury, dubbed Strategy, remains substantially underwater as Saylor signals another bitcoin ...
As AI spending surges, a handful of ETFs offer broad, diversified access to the AI boom. Four funds map to the AI sta...
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
Fraudsters increasingly impersonate seniors to access bank funds. Learn how the posed elderly account holder scam unf...
Two Nasdaq-100 trackers offer the same index path, but a small fee delta has produced a 6.86% trailing return gap ove...
Tesla reports a Q2 delivery surge to 480,126 vehicles, topping forecasts and signaling durable demand despite ongoing...
Investors ask whether to buy Domino's stock before a major investor update. This guide breaks down the decision, back...
A Nashville case highlights a troubling form of elder financial exploitation. Learn how scams work, the signs to watc...
A bold bid to stockpile digital assets for national risk management runs into legal and cross-border hurdles, drawing...
A high-profile insider move has many ALAB investors wondering what comes next. This article breaks down the $60.5 mil...
Geopolitical headlines push crude higher while U.S. stock futures retreat, signaling a risk-off shift for portfolios ...